Want to see HK:1066 full AI Analyst Report?
1066 Stock Chart & Stats
HK$3.26
HK$0.03(0.92%)
At close: 4:00 PM EDT
HK$3.26
HK$0.03(0.92%)
Day’s Range― - ―
52-Week RangeHK$2.92 - HK$7.37
Previous CloseN/A
Volume6.46M
Average Volume (3M)10.92M
Market Cap
HK$15.20B
Enterprise ValueHK$20.29K
Total Cash (Recent Filing)HK$9.87B
Total Debt (Recent Filing)HK$5.99B
Price to Earnings (P/E)8.3
Beta1.12
Next Earnings
Aug 25, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend Yield5.21%
Share Statistics
EPS (TTM)0.35
Shares Outstanding4,522,332,500
10 Day Avg. Volume7,849,305
30 Day Avg. Volume10,915,466
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.86
Price to Sales (P/S)1.55
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.50Price Target Upside99.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.32
Revenue Forecast (FY)HK$13.99B
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Strong Balance SheetThe company’s low debt-to-equity ratio provides durable financial flexibility to fund operations, absorb cyclical shocks, and support working capital or capex without resorting to dilutive financing. That conservatism sustains credit optionality and long-term stability for 2–6 months and beyond.
Positive Operating Cash GenerationDespite weaker recent momentum, continued positive operating and free cash flow means the business generates internal funds to support dividends, maintenance capex and working capital. Persistent cash generation underpins capital allocation and resilience over the medium term.
Defensive Consumables Business ModelAs a supplier of disposable medical consumables to hospitals, the company benefits from recurring, necessity-driven demand and established clinical procurement channels. This product mix supports predictable revenue streams and higher customer stickiness versus cyclical end-markets.
Bears Say
Sharp 2025 Revenue DeclineA 40.5% revenue drop in 2025 indicates significant structural or demand setbacks that can erode pricing power, utilization of fixed-cost capacity and long-term customer relationships. Recovering lost revenue bases can take multiple quarters and strain margins and investment plans.
Sustained Margin And ROE ErosionDeclining gross and net margins alongside halved ROE reflect persistent pricing pressure, cost inflation or mix shifts that reduce capital efficiency. If margins do not stabilize, the company will have less internal cash to reinvest, limiting growth and shareholder returns over the medium term.
Weakening Cash-flow Momentum And Data GapsA material drop in FCF growth and missing 2025 conversion metrics reduce visibility into sustainable cash conversion. Lower cash momentum constrains capital allocation flexibility and increases reliance on balance-sheet buffers, raising execution risk for investments or payouts.
Shandong Weigao Group Medical Polymer Co News
1066 FAQ
What was Shandong Weigao Group Medical Polymer Co Ltd Class H’s price range in the past 12 months?
Shandong Weigao Group Medical Polymer Co Ltd Class H lowest stock price was HK$2.92 and its highest was HK$7.37 in the past 12 months.
What is Shandong Weigao Group Medical Polymer Co Ltd Class H’s market cap?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s market cap is HK$15.20B.
When is Shandong Weigao Group Medical Polymer Co Ltd Class H’s upcoming earnings report date?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s upcoming earnings report date is Aug 25, 2026 which is in 17 days.
How were Shandong Weigao Group Medical Polymer Co Ltd Class H’s earnings last quarter?
Shandong Weigao Group Medical Polymer Co Ltd Class H released its earnings results on Mar 27, 2026. The company reported HK$0.151 earnings per share for the quarter, missing the consensus estimate of HK$0.209 by -HK$0.058.
Is Shandong Weigao Group Medical Polymer Co Ltd Class H overvalued?
According to Wall Street analysts Shandong Weigao Group Medical Polymer Co Ltd Class H’s price is currently Undervalued.
Does Shandong Weigao Group Medical Polymer Co Ltd Class H pay dividends?
Shandong Weigao Group Medical Polymer Co Ltd Class H pays a Semiannually dividend of HK$0.069 which represents an annual dividend yield of 5.21%. See more information on Shandong Weigao Group Medical Polymer Co Ltd Class H dividends here
What is Shandong Weigao Group Medical Polymer Co Ltd Class H’s EPS estimate?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s EPS estimate is 0.2.
How many shares outstanding does Shandong Weigao Group Medical Polymer Co Ltd Class H have?
Shandong Weigao Group Medical Polymer Co Ltd Class H has 4,522,332,500 shares outstanding.
What happened to Shandong Weigao Group Medical Polymer Co Ltd Class H’s price movement after its last earnings report?
Shandong Weigao Group Medical Polymer Co Ltd Class H reported an EPS of HK$0.151 in its last earnings report, missing expectations of HK$0.209. Following the earnings report the stock price went up 3.148%.
Which hedge fund is a major shareholder of Shandong Weigao Group Medical Polymer Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1066
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Weigao Group Medical Polymer Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.57%
12-Months-Change
Fundamentals
Return on Equity
5.21%
Trailing 12-Months
Asset Growth
8.32%
Trailing 12-Months
Company Description
Shandong Weigao Group Medical Polymer Co Ltd Class H
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.
1066 Stock 12 Month Forecast
Average Price Target
HK$6.50
▲(99.39% Upside)
Technical Analysis
PW Medtech Group Ltd.
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―
OrbusNeich Medical Group Holdings Limited
―








